| __timestamp | Halozyme Therapeutics, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 7459000 |
| Thursday, January 1, 2015 | 93236000 | 11831000 |
| Friday, January 1, 2016 | 150842000 | 25705000 |
| Sunday, January 1, 2017 | 150643000 | 46181000 |
| Monday, January 1, 2018 | 150252000 | 59497000 |
| Tuesday, January 1, 2019 | 140804000 | 65003000 |
| Wednesday, January 1, 2020 | 34236000 | 74506000 |
| Friday, January 1, 2021 | 35672000 | 126006000 |
| Saturday, January 1, 2022 | 66607000 | 126215000 |
| Sunday, January 1, 2023 | 76363000 | 120161000 |
| Monday, January 1, 2024 | 79048000 |
In pursuit of knowledge
In the competitive world of biotechnology, investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, Halozyme Therapeutics, Inc. and Protagonist Therapeutics, Inc. have demonstrated varying levels of commitment to R&D. From 2014 to 2023, Halozyme consistently led in R&D spending, peaking in 2016 with a 150% increase from 2014. However, Protagonist has shown remarkable growth, with a staggering 1,600% increase in R&D expenses from 2014 to 2023, surpassing Halozyme in recent years. This shift highlights Protagonist's aggressive push towards innovation, especially notable in 2021 and 2022 when their R&D spending exceeded Halozyme's by over 80%. As these companies continue to innovate, their R&D investments will likely play a pivotal role in shaping their future success and the biotech landscape.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Sanofi vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
R&D Spending Showdown: Incyte Corporation vs Protagonist Therapeutics, Inc.
Research and Development Investment: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc. vs MiMedx Group, Inc.: Strategic Focus on R&D Spending